RxDoctor Payments Data

Benjamin Abinales, MD

Internal Medicine · St Petersburg, FLNPI 1144458977

Payments from drug & device makers

$1,049in general payments, 2019–2025

Across 72 payments — averaging $14.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$514
  • Novo Nordisk$287
  • Pfizer$36
  • GSK$35
  • Eisai Inc.$29
  • Zimmer Biomet$27
  • plus $121 from 8 others

What the payments were for

  • Food & beverage$1,049100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,049 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$339,452
Medicare patients
565
Services billed
4,148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban507$320,445
OzempicSemaglutide183$219,630
XareltoRivaroxaban123$80,757
JanuviaSitagliptin Phosphate84$70,445
CreonLipase/Protease/Amylase12$54,530
MounjaroTirzepatide45$49,276
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$47,391
MyrbetriqMirabegron69$42,353
NuedextaDextromethorphan Hbr/Quinidine34$37,979
JardianceEmpagliflozin32$31,156
Breo ElliptaFluticasone/Vilanterol67$30,749
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog35$27,236
ProliaDenosumab12$20,861
ViberziEluxadoline12$20,320
GemtesaVibegron42$18,886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$36$320,445507 claims
Novo NordiskOzempic$287$219,630183 claims
AbbVieCreon, Viberzi, Linzess, Namzaric$514$96,83159 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$35$88,837148 claims
Lilly USA, LLCMounjaro$18$49,27645 claims
Astellas Pharma US IncMyrbetriq$16$42,35369 claims
Boehringer IngelheimJardiance, Combivent Respimat$14$37,50245 claims
AstraZenecaBrilinta, Symbicort, Farxiga$12$30,61073 claims
Sumitomo Pharma America, Inc.Gemtesa$18$18,88642 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →